












434Seroprotective Titers against 2009 H1N1 Influenza
A Virus after Vaccination in Allogeneic Hematopoietic
Stem Cell Transplantation Recipients
Nicolas C. Issa,1,2 Francisco M. Marty,1,2 Lisa S. Gagne,1 Sophia Koo,1,2
Kelly A. Verrill,1 Edwin P. Alyea,2 Corey S. Cutler,1,2 John Koreth,2 Philippe Armand,2
Vincent T. Ho,2 Joseph H. Antin,2 Robert J. Soiffer,2 Lindsey R. Baden1,2Little data are available regarding the safety and immunologic response to pandemic H1N1 influenza vaccine
in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). We measured serum antibody
titers against A/California/7/2009 H1N1 using a hemagglutination inhibition assay in 82 allogeneic HSCT
recipients who received the 2009 H1N1 vaccine between November 2009 and January 2010 after it became
available at our institution. The median time between HSCTand vaccination was 19 months (range, 2.5-94
months), and the median time from vaccination to specimen collection was 56 days (range, 14-140 days).
Seroprotective antibody titers (hemagglutination inhibition titer$1:40) against 2009 H1N1 influenza A virus
were detected in 51% of patients. The presence of chronic graft-versus-host disease and type of conditioning
regimen did not affect the rate of detection of seroprotective titers after vaccination. Patients were more
likely to have a seroprotective titer the farther away from HSCT they were (adjusted odds ratio, 1.79 per
year; 95% confidence interval, 1.12-2.85). Rituximab administration in the year before vaccination was
associated with a lack of seroprotective titer (adjusted odds ratio, 0.11; 95% confidence interval, 0.01-
0.97). The vaccine was safe and well tolerated. Strategies are needed to improve the influenza vaccine re-
sponse in this population, especially those receiving immunotherapy.
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Influenza A is an important pathogen in allogeneic
hematopoietic stem cell transplantation (HSCT) re-
cipients, with reported rates of pneumonia of 29%-
80% and case fatality rates of 10%-25% [1-7]. In
April 2009, a novel H1N1 influenza A virus of swine
origin was identified in Mexico and spread rapidly
throughout the world, reaching pandemic levels.
Given that the 2009 H1N1 virus continues to
circulate globally, and the fact that the 2009 H1N1
antigen will be a component of the standard influenza
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H1N1 vaccination in allogeneic HSCT recipients at
our institution, and examined factors associated with
the serologic response in this population.MATERIALS AND METHODS
Outpatient allogeneic HSCT recipients at our in-
stitution who received unadjuvanted 2009 H1N1
vaccine (15 mg of hemagglutinin antigen, lot nos.
102046P1, 102130P1, 102131P1, and 102138P1; No-
vartis Vaccines, Cambridge, MA) between November
2009 and January 2010 were studied. Only serum
samples collected at subsequent clinic visits between
December 2009 and April 2010 were analyzed. No
baseline (ie, prevaccination) serum samples were
available. This study was approved by the Office for
Human Research Studies at Dana-Farber/Harvard
Cancer Center.
Pertinent clinical data, including patient demo-
graphic information, underlying diseases, graft donor
source and date, conditioning regimen, graft-versus-host
disease (GVHD), immunosuppressant use, previous
influenza vaccinations, influenza-like illnesses, use of
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enza infection between April 2009 and blood
collection time, and any adverse events potentially
associated with H1N1 vaccination, were recorded.
Anti-influenza antibody titers were measured by Focus
Diagnostics (Cypress, CA) using a standard hemagglu-
tination inhibition (HAI) assay [8]. All specimens were
tested in triplicate against H1N1: A3/California/7/
2009, H1N1: A1/Brisbane/59/2007, H3N2: A2/
Brisbane/10/2007, and B strain: B/Brisbane/60/2008.
The primary immunogenicity endpoint was the pro-
portion of subjects with a geometric mean antibody
titer of$1:40, which is the typical minimum titer asso-
ciated with protection as defined by the Centers for
Disease Control and Prevention and the Food and
Drug Administration [8]. Logistic regression was
used for univariate andmultivariate analyses. All statis-
tical analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC).RESULTS
Serum samples from 82 allogeneic HSCT recipi-
ents who returned to clinic following receipt of the
2009 H1N1 vaccination during the study period
were available for analysis. Clinical characteristics are
summarized in Table 1. Two additional patients had
documented H1N1 influenza before vaccination and
were excluded from the analysis; both had high HAI
titers. Patients received the vaccination and returned
for follow-up at the discretion of the treating physi-
cian. The median patient age at the time of vaccination
was 55 years (range, 20-71 years). Themedian time be-
tween HSCT to vaccination was 578 days (interquar-
tile range [IQR], 358-879 days; range, 77-2819 days),
and the median time between vaccination and speci-
men collection was 56 days (range, 14-140 days).
The median donor age was 40 years (IQR, 30-47 years;
range, 23-65 years). Forty-one patients had chronic
GVHD at time of vaccination, and two patients had
acute GVHD. Sixty-one patients were receiving an im-
munosuppressive medication at time of vaccination.
Thirty-two patients had received the 2009 seasonal
influenza vaccine.
Seroprotective titers (HAI titer $1:40) against
2009 H1N1 influenza A virus were detected in
51.2% of the patients (Table 1). Figure 1 presents
the HAI titer distribution in the study group. HAI
titers $1:40 to the seasonal influenza strains were
variable: 50% to 2007 H1N1, 57.3% to 2007 H3N2,
and 20.7% to 2008 B.
Age $60 years, sex, race/ethnicity, HSCT type
(donor source), conditioning regimen, presence or
absence of GVHD, type of immunosuppression,
previous seasonal influenza vaccination, history of
influenza-like illness, or history of oseltamivirtreatment did not influence the rate of achieving
a seroprotective titer against 2009 H1N1 on univariate
or multivariate analysis. The relevant factors affecting
seroprotection against 2009 H1N1 are summarized in
Table 2. Of note, no patient studied underwent T cell–
depleted transplantation. In the year before vaccina-
tion, rituximab was administered to 7 patients as part
of a clinical trial for chronic GVHD prophylaxis and
to 4 patients who received rituximab to treat chronic
GVHD. Rituximab therapy (375 mg/m2) in the year
preceding vaccination was associated with a signifi-
cantly diminished rate of seroprotective titers to the
2009 H1N1 vaccination (9.1%; adjusted odds ratio
[OR], 0.11; 95% confidence interval [CI], 0.01-0.97;
P5 .04). Patients who received mycophenolate mofe-
til (MMF) therapy had a lower rate of seroprotective
titers compared with those who did not receive
MMF (33.3% vs 56.2%); however, the difference was
not statistically significant (P 5 .11). Seroprotective
titer rates were higher in patients with longer intervals
between HSCT and vaccination (adjusted OR, 1.79
per year after HSCT; 95% CI, 1.12-2.85; P 5 .01).
The rate of seroprotection was 37% in patients who
received the 2009 H1N1 vaccine less than 6 months
after HSCT, 50.0% in those who did so between 6
months and 1 year after HSCT, 38.7% in those who
did so between 1 and 2 years afterHSCT, 69% in those
who did so more than 2 years after HSCT. The 2009
H1N1 vaccine was safe and well tolerated; no signifi-
cant vaccine associated adverse events were noted.
No patient had confirmed H1N1 influenza infection
from the time of vaccination to the time of specimen
collection.DISCUSSION
The serologic response rate to the seasonal influ-
enza vaccine and the clinical efficacy of vaccination
are reportedly influenced by various factors, including
age, timing of vaccination after HSCT, GVHD, and
exposure to immunosuppressant medications (eg,
steroids, rituximab, alemtuzumab) [9-14]. A poor
serologic response to vaccine antigens has been
documented in HSCT recipients receiving seasonal
influenza vaccination within the first 6 months after
HSCT [11]. A comparison of humoral and cellular
immune responses to influenza vaccination in HSCT
recipients and healthy volunteers revealed that overall,
the HSCT recipients had a lower protective humoral
response to the vaccination, with a particularly dimin-
ished response seen in those vaccinated within the first
6 months after transplantation; however, the vaccine
still elicited a strong T cell–mediated immune re-
sponse in both groups [10,15]. We found a 37% rate
of seroprotection in the patients who received 2009
H1N1 vaccination less than 6 months after HSCT;
Table 1. Patient Characteristics and Serologic Response Rates to the 2009 H1N1 Vaccination
n %
Seroprotective Titers (HAI Titer $1:40)
against 2009 H1N1 Influenza A Virus P Value
Number of patients 82 100% 51.2%
Median age, years (IQR, range) 55 (47-61, 20-71)
<60 56 68.3% 51.8% 1.00
$60 26 31.7% 50.0%
Sex
Male 40 48.8% 45.0% .38
Female 42 51.2% 57.1%
Race/ethnicity .71
White 76 92.7% 52.6%
Nonwhite 6 7.3% 33.3%
Black 4 4.9%
Asian 2 2.4%
Donor age, years (IQR, range) 40 (30-47, 23-65)
Underlying disease
Acute myelogenous leukemia 26 31.7% 57.7%
Chronic lymphoblastic leukemia 12 14.6% 41.7%
Myelodysplastic syndrome 12 14.6% 41.7%
Non-Hodgkin lymphoma 10 12.2% 40.0%
Aacute lymphoblastic leukemia 10 12.2% 30.0%
Chronic myelogenous leukemia 4 4.9% 75.0%
Multiple myeloma 4 4.9% 75.0%
Other 4 4.9% 100.0%
Type of transplantation .19
Matched related donor 35 42.7% 60.0%*
Unrelated donor 47 57.3% 44.7%*
Matched unrelated donor 35 42.7% 45.7%
Mismatched unrelated donor 9 11.0% 44.4%
Cord blood transplant 3 3.7% 33.3%
Conditioning regimen
Myeloablative 38 46.3% 47.4% .66
Nonmyeloablative 44 53.7% 54.5%
GVHD at vaccination
No GVHD 39 47.6% 59.0% .19
Any GVHD 43 52.4% 44.2%
Acute 2 2.4%
Chronic 41 50.0%
Immunosuppression at time of vaccination 61 74.4% 47.5% .32
None 21 25.6% 61.9%
Tacrolimus 46 56.1% 50.0% .83
No tacrolimus 36 43.9% 52.8%
Sirolimus 28 34.1% 53.6% .82
No sirolimus 54 65.9% 50.0%
MMF 18 21.9% 33.3% .11
No MMF 64 78.1% 56.2%
Prednisone 45 54.9% 44.4% .19
No prednisone 37 45.1% 59.5%
Past season influenza vaccination
2009 32 39.0% 43.7% .36
No 2009 50 61.0% 56.0%
2008 31 37.8% 58.1% .37
No 2008 51 62.2% 47.1%
2007 17 20.7% 70.6% .10
No 2007 65 79.3% 46.1%
2006 11 13.4% 63.6% .52
No 2006 71 86.6% 49.3%
Median time from HSCT to vaccination, days 578
IQR, 358-879
Range, 77-2819
Time from HSCT to vaccination .09
<6 months 8 9.8% 37.5%
6 months-1 year 14 17.0% 50.0%
1-2 years 31 37.8% 38.7%
> 2 years 29 35.4% 69.0%






vaccination date and sampling date
6 7.3% 33.3%
No intravenous immunoglobulin 76 92.7% 52.6% .43
(Continued )
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Table 1. (Continued )
n %
Seroprotective Titers (HAI Titer $1:40)
against 2009 H1N1 Influenza A Virus P Value
Rituximab within 1 year before vaccination 11 13.4% 9.1% .003
No rituximab 71 86.6% 57.7%
Alemtuzumab 1 1.2% 0% .49
No alemtuzumab 81 98.8% 51.8%
Influenza-like illness 16 19.5% 43.7% .58
No influenza-like illness 66 80.5% 53.0%
Causes of influenza-type illness
Respiratory syncytial virus 1 1.2%
Parainfluenza 2 2.4%
Unknown 13 15.8%
History of exposure 1 1.2%
Oseltamivir treatment 8 9.8% .48
Influenza testing
Negative 14 17.0%
Not performed 68 83.0%
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seasonal trivalent influenza vaccination in our cohort
(39% in 2009, 37.8% in 2008, 20.7% in 2007, and
13.4% in 2006) makes it difficult to discern the overall
vaccine immune response to these antigens versus
possible previous seasonal influenza infection. Overall,
seroprotection against all of the influenza viruses
observed was modest, even in patients who received
the trivalent vaccine, with particularly low titers to
influenza B, consistent with previous reports [16,17].
In our study cohort, the overall rate of seroprotec-
tion after 2009 H1N1 vaccination was modest (51.2%)
compared with the rate of 96.7% (95% CI, 91.7%-
98.7%) observed in the general population [8].
Historically, the response rate to seasonal influenza
vaccination in HSCT recipients has been found to be
blunted compared with healthy individuals (29%-
34% vs 46%-62%) [12]. Rituximab therapy initiated
within 1 year of vaccination was significantly associ-
ated with a decreased rate of seroprotective titers.
This finding might be attributed to the prolonged de-
pletion of B lymphocytes after rituximab administra-
tion [18], or might be related to loss of antigen
presentation or B cells’ function. A poor response to
seasonal influenza vaccination has been reported in
patients who received rituximab or alemtuzumab ther-
apy for lymphoma [9]. As reported previously withFigure 1. Reverse cumulative distribution curve of HAI titers.seasonal influenza vaccination [11], a longer interval
betweenHSCT and influenza vaccination is correlated
with better serologic response to the 2009 H1N1 in-
fluenza vaccination, with an increasing OR of 1.79
(95% CI, 1.12-2.85) per year after HSCT for achiev-
ing a seroprotective level. Importantly, the presence
of chronic GVHD, concurrent immunosuppressive
therapy (including prednisone), and the type of condi-
tioning regimen did not influence the rate of seropro-
tection against 2009 H1N1 influenza virus in our
cohort. Previous studies found lower titers in patients
with GVHD and patients who received more intensive
conditioning regimens [11,14]; although these
observations are plausible, the small number of
patients makes the data less reliable.
Although our analysis lacks baseline 2009 H1N1
antibody titers because it was carried out in an epi-
demic setting, with vaccinations administered as they
became available, it is highly unlikely that our findings
were affected by preexisting immunity to H1N1 from
infection. Such an effect would lead to an overestima-
tion of the seroprotective titer rate. Preexisting anti-
body titers against 2009 H1N1 influenza A virus in
up to 34% of individuals born before 1950 have been
reported [19]; however, our data show no difference
in the seroprotective titer rate between patients or
donors older and younger than age 60. We also found
no difference in the seroprotective titer rate between
patients with and without an influenza-like illness,
patients with and without oseltamivir therapy, and pa-
tients with and without seasonal influenza vaccination.
In 2 recent studies, vaccination with seasonal nonadju-
vanted or adjuvanted influenza vaccines induced little
or no cross-reactive antibody response to 2009
H1N1 in any age group [19,20]. The 2009 H1N1
vaccine proved safe and well tolerated, with no
significant vaccine-associated adverse events noted,
in agreement with another study [21].
In summary, we found a modest rate of seroprotec-
tive titers against 2009 H1N1 influenza virus in our
Table 2. Seroprotective Titers against 2009 H1N1 Influenza AVirus and the Influence of Relevant Variables
Variable n 2009 H1N1 Titer $1:40 Univariate OR (95% CI) Multivariate OR (95% CI) P Value
Age $60 years 26 50.0% 0.93 (0.37-2.36) 0.93 (0.31-2.78) .89
GVHD 43 44.2% 0.55 (0.23-1.32) 0.59 (0.14-2.43) .47
Rituximab use within 1 year of vaccination 11 9.1% 0.07 (0.009-0.60) 0.11 (0.01-0.97) .04
MMF use 18 33.3% 0.39 (0.13-1.16) 0.41 (0.09-1.80) .24
Prednisone use 45 44.4% 0.54 (0.23-1.32) 0.80 (0.22-2.98) .74
Time to vaccination, per year after HSCT — — 1.58 (1.09-2.30) 1.79 (1.12-2.85) .01
438 Biol Blood Marrow Transplant 17:434-438, 2011N. C. Issa et al.cohort of allogeneic HSCT recipients. Based on these
data, administration of influenza vaccination relatively
early after transplantation should be considered in all
HSCT recipients. Given the modest response rate,
strategies to improve influenza vaccine response are
needed, and patients should continue to use protective
measures to prevent viral respiratory infections. These
data further demonstrate the impact of rituximab on
the response to the influenza vaccine and may have
implications for the response to other vaccines as well.ACKNOWLEDGMENTS
We thank David W. Kubiak, PharmD, BCPS,
Anne McDonnell, PharmD, Emily Mui, PharmD,
and Juliette Kim, PharmD for their help in retrieving
pharmacy data on vaccine administration oseltamivir,
intravenous immunoglobulin, rituximab, and alemtu-
zumab use. This study was supported in part by Na-
tional Cancer Institute Grant CA142106 and the Jock
and Bunny Adams Education and Research Fund.
Financial disclosure: The authors have no conflicts
of interest to disclose.REFERENCES
1. Ljungman P. Respiratory virus infections in bone marrow trans-
plant recipients: the European perspective.Am JMed. 1997;102:
44-47.
2. Ljungman P. Respiratory virus infections in stem cell transplant
patients: the European experience. Biol Blood Marrow Transplant.
2001;7(Suppl):5S-7S.
3. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus
infections after stem cell transplantation: a prospective study
from the Infectious Diseases Working Party of the European
Group for Blood and Marrow Transplantation. Bone Marrow
Transplant. 2001;28:479-484.
4. Nichols WG, Guthrie KA, Corey L, et al. Influenza infections
after hematopoietic stem cell transplantation: risk factors,
mortality, and the effect of antiviral therapy. Clin Infect Dis.
2004;39:1300-1306.
5. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus
infections among hospitalized adult bone marrow transplant
recipients. Bone Marrow Transplant. 1994;13:437-440.6. Bowden RA. Respiratory virus infections after marrow trans-
plant: the FredHutchinson Cancer Research Center experience.
Am J Med. 1997;102:27-30.
7. Champlin RE,Whimbey E. Community respiratory virus infec-
tions in bone marrow transplant recipients: the M.D. Anderson
Cancer Center experience. Biol Blood Marrow Transplant. 2001;
7(Suppl):8S-10S.
8. GreenbergME, Lai MH,Hartel GF, et al. Response to a mono-
valent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;
361:2405-2413.
9. Ljungman P, Nahi H, Linde A. Vaccination of patients with
haematological malignancies with one or two doses of influenza
vaccine: a randomised study. Br J Haematol. 2005;130:96-98.
10. Ljungman P, Avetisyan G. Influenza vaccination in hematopoi-
etic SCT recipients. Bone Marrow Transplant. 2008;42:637-641.
11. Engelhard D, Nagler A, Hardan I, et al. Antibody response to
a two-dose regimen of influenza vaccine in allogeneic T cell-
depleted and autologous BMTrecipients.BoneMarrowTransplant.
1993;11:1-5.
12. Pauksen K, Linde A, Hammarstrom V, et al. Granulocyte mac-
rophage colony-stimulating factor as immunomodulating factor
together with influenza vaccination in stem cell transplant
patients. Clin Infect Dis. 2000;30:342-348.
13. Fiore AE, Shay DK, Broder K, et al. Prevention and control of
influenza: recommendations of the Advisory Committee on
Immunization Practices (ACIP), 2008. MMWR Recomm Rep.
2008;57(RR-7):1-60.
14. Machado CM, Cardoso MR, da Rocha IF, et al. The benefit of
influenza vaccination after bone marrow transplantation. Bone
Marrow Transplant. 2005;36:897-900.
15. Avetisyan G, Aschan J, Hassan M, et al. Evaluation of immune
responses to seasonal influenza vaccination in healthy volunteers
and in patients after stem cell transplantation. Transplantation.
2008;86:257-263.
16. Yalcin SS, Kondolot M, Albayrak N, et al. Serological response
to influenza vaccine after hematopoetic stem cell transplanta-
tion. Ann Hematol. 2010 Sep;89(9):913-918.
17. Egoz N, Morag B, KlingbergW, et al. Influenza immunization:
serologic and clinical responses in military units. Infection. 1977;
5:71-75.
18. Cerny T, Borisch B, Introna M, et al. Mechanism of action of
rituximab. Anticancer Drugs. 2002;13(Suppl 2):S3-S10.
19. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody
responses to the 2009 pandemic H1N1 influenza virus. N Engl
J Med. 2009;361:1945-1952.
20. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, et al.
Infection and death from influenza A H1N1 virus in Mexico:
a retrospective analysis. Lancet. 2009;374:2072-2079.
21. Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1
influenza infection in cancer patients and hematopoietic stem
cell transplant recipients. J Infect. 2010 Apr;60(4):257-263.
